Biocius and BlueSky to Develop Sirtuin Enzymes Validated Using Label-Free Assays | GenomeWeb

Biocius Life Sciences and BlueSky Biotech this week announced a collaboration to provide sirtuin enzyme preparations that have been fully validated via a label-free functional assay.

The collaboration, which builds on an existing partnership between the two companies, has the potential to improve the drug discovery efficiency of SIRT epigenetic modulating enzymes — which have been implicated in processes such as insulin signaling, apoptosis, and cancer — the companies said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.